More News

Alcon Aims to Extend Ultrasonic Phaco Dominance with Launch of Unity CS

Alcon launched the Unity VCS and CS machines in April at the annual meeting of the American Society of Cataract and Refractive Surgery, looking to continue its global dominance in the cataract mach...

Chinese Companies Launch Wave of New Ophthalmic Products at Home

China’s ophthalmic market is riding a wave of new Chinese offerings, spurred on by policies promoting the locali-zation of medical products. New products from Chinese companies approved by the Nati...

Ophthalmic Venture Capital Continues to Bounce Back, Driven by Retinal Pharma

Venture capital investments accounted for 96 percent of ophthalmic deals in Q2-2025, with financing rounds totaling $590.7 million—the highest quarter since Q3-2023, when these transactions reached...

Alcon to Acquire LumiThera and Its Photobiomodulation Device for Dry AMD

Alcon announced July 7 that it intended to acquire LumiThera and its photobiomodulation (PBM) device that targets early and intermediate dry age-related macular degeneration (AMD). No financial det...

J&J Vision Launches Tecnis Odyssey PC-IOL in Europe, Middle East, and Canada

Johnson & Johnson Vision announced June 17 that it had rolled out the Tecnis Odyssey presbyopia-correcting intraocular lens (PC-IOL) in Europe, the Middle East, and Canada. The Odyssey had previous...

Select US FDA Approvals and Clearances in June 2025

The US FDA’s ophthalmic device division granted clearance to three devices using the 510(k) pathway in June 2025, according to the agency’s database. Zeiss received clearance for its Micor 700 syst...

Harrow Secures US Rights to Retinal Biosimilars Byooviz and Opuviz

Harrow announced July 17 that it had secured exclusive US commercial rights to Samsung Bioepis’ FDA-approved ophthalmology biosimilars—Byooviz (ranibizumab-nuna) and Opuviz (aflibercept-yszy). No f...

ForSight Leads Latest Ophthalmic Fundraising with $125 Million in Series B

Israel’s ForSight Robotics led recent ophthalmic fundraising efforts with $125 million in Series B funding as it prepares its robotic cataract surgery system for human trials. Financing announced i...

Retina Researchers Urge J&J to File for Approval of XLRP Gene Therapy Despite Failed Trial

Investigators in the Phase III LUMEOS trial, with backing from the Foundation Fighting Blindness, issued a statement June 6 exhorting Johnson & Johnson to file for US FDA approval of bota-vec, a ge...

Premium Presbyopia Treatment Rates Remain Low Despite New Product Launches

The presbyopia treatment market is growing due to recent advancements in intraocular lenses (IOLs) and FDA-approved pharmacological drops. Despite this, treatment rates (the number of premium proce...

EyeDura Wins Two Octane Awards for Sustained-Release Eye Drop Platform

EyeDura Therapeutics earned the judges’ top award during Octane’s capital and growth company presentations, which spotlighted early-stage, high-potential ophthalmic ventures. The company was a favo...

Baruch Kuppermann, MD, PhD, Receives 2025 Roger Steinert, MD, Legacy Award

Baruch Kuppermann, MD, PhD, was honored at the Octane meeting as the recipient of the 2025 Roger Steinert, MD, Legacy Award, which recognizes significant leadership, innovation, and enduring contri...

Clearside Explores Strategic Alternatives, Transitions Workforce

Clearside Biomedical reported July 17 that it was exploring strategic alternatives to continue advancing its suprachoroidal space delivery platform and ophthalmic pipeline, while transitioning all ...

Health Insurers Pledge to Reform Prior Authorization by 2026

Major insurers of nearly 50 US health plans published a pledge on June 24 to simplify and reduce prior authorization of medical treatments, cutting the volume of treatments subject to such oversigh...

OpRegen’s Phase I/IIa Trial in GA Shows Mean Improvement in VA Through 36 Months

Lineage Cell Therapeutics reported on June 23 that patients with geographic atrophy who were treated with OpRegen cell therapy in a Phase I/IIa clinical study showed mean improvement in visual acui...

Presbyopia Drop Candidate from Viatris and Opus Meets Endpoints in Second Phase III Trial

Commercial partners Viatris and Opus Genetics reported June 26 that their presbyopia drop candidate, MR-141 (phentolamine ophthalmic solution 0.75%), met its primary endpoint and key secondary endp...

Clinical Trial Updates for Ophthalmic Candidates, July 2025

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

DEWS III Report Updates Guidelines for Diagnosis and Management of Dry Eye

The Tear Film and Ocular Surface Society (TFOS) has released DEWS III, its third set of reports exploring the diagnosis and management of dry eye disease. The findings of the TFOS Dry Eye Workshop ...

Emerging Companies Pursuing Ophthalmic Indications, July 2025

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Iridex Reports Start of UK Trial Using MicroPulse with Anti-VEGF Injections in DME

Iridex reported June 24 that an independent, investigator-led UK study evaluating MicroPulse technology as an adjunct to anti-VEGF therapy in diabetic macular edema (DME) had enrolled its first pat...

PDUFA Dates for Ophthalmic Drug Candidates, July 2025

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.

Weekly Surgeon Poll, July 2025

July 2025 Ophthalmic News Briefs

Hoya Vision Care announced June 2 that it had acquired Centennial Optical, a Canadian distributor of ophthalmic frames, eyeglass lenses, sunglasses, lab supplies, and optical accessories. Financial...